抗HBV-DC治疗e抗原阴性慢性HBV感染者的初步临床研究  

Clinical research on the treatment effect of anti-HBV dendritic cell on e antigen negative patients with chronic HBV infection

作　　者：吴邦富[1] 杨江英[1] 周赟 温凌[1] 肖间开[1] 彭英宇 杨军 

机构地区：[1]广州市第十二人民医院,广东广州510620 [2]广州普邦生物免疫技术研究中心,广东广州510620

出　　处：《中国医药导报》2008年第2期68-69,160,共3页China Medical Herald

摘　　要：目的:观察HBsAg致敏患者自体外周血单个核细胞(PBMC)来源的树突状细胞(DC)(简称抗HBV-DC)治疗e抗原阴性慢性乙型肝炎病毒(HBV)感染者的临床效果。方法:4例轻度慢性乙型肝炎(CHB)患者、5例慢性HBV携带者及17例非活动性HBsAg携带者接受临床试验。检测治疗前后HBV标志物定量、HBV-DNA定量及肝功能,两次检测平均间隔40d。结果:治愈5例,好转21例,有效率为100%,治愈率19.23%。治疗前后HBsAg分别为(129.58±112.68)ng/ml和(42.67±51.41)ng/ml(t=5.57,P<0.001),平均下降68%,5例HBsAg转阴。7例治疗前HBV-DNA定量高于正常,为(2.17±5.27)×106copies/ml,治疗后6例下降,其中,5例降为正常,1例升高0.49log;原1例HBV-DNA定量正常者升高到1.30×103copies/ml。治疗前后ALT分别为(30.04±19.99)U/L和(40.50±45.10)U/L,有升高趋势(t=1.75,P=0.09),HBsAb、HBeAb、HBcAb及TBIL无显著变化。结论:抗HBV-DC静脉回输可显著降低并清除HBsAg,抑制e抗原阴性慢性HBV感染者的病毒复制,减少病毒载量,清除病毒,彻底治愈慢性HBV感染者。CHB患者、慢性HBV携带者和非活动性HBsAg携带者均可对抗HBV-DC的治疗发生良好的应答反应,是一种安全、高效地治疗e抗原阴性慢性HBV感染者的方法,显示出良好的临床应用前景。延长疗程和增加治疗次数可望进一步提高治愈率。Objective：To investigate the treatment effect of autologous HBsAg-loaded dendritic cells （anti-HBV DCs） on e antigen negatlve patients With Chronic HBV infection. Methods：4 chronic hepatitis B （CHB）, 5 chronic HBV carrier and 17 inactive HBsAg carrier attended the test. HBV markers, HBV DNA level, and liver function tests in the serum of pa- tients were tested before and after treatment. Results：The effective rate was 100%（26/26）, and the cure rate was 19.23%（5/ 26）. The HBsAg levels were （129.58±112.68） ng/ml and （42.67±51.41） ng/ml （t=5.57,P〈0.O01）, and the ALT levels were （30.04±19.99） U/L and （40.50±45.10） U/L（t=l.75, P=0.09）before and after treatment. And 5 patients＇HBsAg were negative after treatment. The HBV-DNA levels of 7 patients whose HBV DNA being abnormal before treatment were （2.17±5.27）×106 copy/ml, and 5/7 patients＇HBV DNA were negative after treatment.Conehlsion：The autologous anti-HBV DCs can effec- tively suppress HBV replication, reduce and eliminate HBV and HBsAg, and cure those e antigen negative patients with chronic HBV infection： CHB, chronic HBV carrier and inactive HBsAg carrier also have a more effective and more safety for anti-HBV DCs treatment. The cure rate may raise a further for extending period of treatment and increasing times of treatment.

关 键 词：树突状细胞 肝炎病毒 乙型 乙型肝炎 

分 类 号：R511[医药卫生—内科学]